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1. Introduction 
Drug-induced acute pancreatitis (DIP) is generally considered to be a rare disease. Indeed, 
the incidence of cases caused by medication use is much lower than of those caused by 
biliary disorder or alcohol. On the other hand, the total incidence of acute pancreatitis in 
developed countries continues to rise as does the exposition of general population to 
medication. The disease was almost unknown before the 1960s. Probably the first two cases 
were reported in the late 1950s: by Zion et al. in 1955 and Johnston & Cornish in 1959. From 
that time, the number of reported cases has increased steadily until these days. A further 
increase in the incidence of drug-induced acute pancreatitis may be expected and seems to 
be actually present in recent scientific papers on the topic. 
For a proper understanding of the disease, we must regard it not simply as one of many 
other types of acute pancreatitis, but primarily as an adverse drug reaction (ADR). A recent 
definition describes an ADR as “an appreciably harmful or unpleasant reaction, resulting 
from an intervention related to the use of a medicinal product, which predicts hazard from 
future administration and warrants prevention or specific treatment, or alteration of the 
dosage regimen, or withdrawal of the product” (Edwards & Aronson, 2000).  
 
Type of 
ADR 
Mnemonic Dose dependence / 
Predictability 
Characteristics 
A Augmented Dose-related, predictable Most usual; frequent 
B Bizarre Dose-unrelated, 
unpredictable 
Immunity-mediated reactions or 
idiosyncrasies; rare 
C Continuous Related to a cumulative 
dose and time 
Effect of chronic use, late toxicity 
D Delayed Related to time Long time from drug cessation 
E End of use Related to drug 
withdrawal 
Immediately after withdrawal 
Table 1. Types of adverse drug reactions 
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The vast majority of the reported DIP cases seem to have an idiosyncratic character (see 
Table 1). This also means that it is nearly impossible to obtain sufficiently large cohorts with 
similar patient characteristics. From that point of view, every case of drug-induced 
pancreatitis should be documented as well as possible, and also reported to a 
pharmacovigilance system for further evaluation. 
2. Epidemiology 
It is usually estimated that drug use accounts for 2% of all the causes of acute pancreatitis. It 
must be pointed out that the diagnosis might be underestimated, particularly for the 
difficulties in diagnosing this etiology. The overall incidence varies in different studies from 
0.1 to 2% with a tendency to increase over time (Balani et al, 2008).  
There are three sources of information on the DIP incidence: data from clinical studies on 
acute pancreatitis, individual or serial case reports published in medical journals, and data 
on spontaneous reports from pharmacovigilance databases. Another possible source – data 
from clinical testing of new drugs – is not very useful because of an idiosyncratic character 
of DIP. The B-type of adverse drug reactions occurs with a frequency lower than 1:10,000, so 
their record in the first three phases of clinical drug investigation is almost impossible. 
The number of cases reported to pharmacovigilance databases and of published case reports 
is increasing so rapidly that any number will be obsolete by the time it manages to be 
printed. According to Lancashire et al., the WHO database of ADRs listed 2,479 episodes 
suspected of being caused by 529 different drugs from 1968 to 1993. An analysis of the DIP 
cases reported to the Danish Committee on Adverse Drug Reactions from 1968 to 1999 
(Andersen et al., 2001) showed an increasing number of reports in time and a predominance 
of women, but estimating the proportion of DIP in total acute pancreatitis incidence is 
clearly improper. The mortality of 9% among the cases analyzed shows a tendency to report 
the most severe cases, whilst the majority of mild-to-moderate cases remain unreported. On 
the other hand, an information bias, due to more frequent notification of a drug already 
known to cause a specific ADR, is limiting the validity of spontaneous reporting. A Medline 
search of the English literature revealed 1,214 case reports with 120 suspected drugs 
between 1955 and 2006 (Badalov et al., 2007). The weakness of estimating DIP incidence 
from these sources is in preferential publication of the case reports describing ADRs of new 
– therefore more “attractive” – agents rather than of older ones in which the risk is 
considered to be well-known. 
In a multicenter study by Gullo et al., published 2002, in which the etiology and mortality of 
acute pancreatitis were studied, the proportion of drug injury was almost negligible: only 
0.2% (2 patients) out of 1,068 cases. It is worth noting that three out of the seven centers 
involved in this study (providing 581 AP cases for the study) were surgical departments; 
moreover, 139 (13%) cases of acute pancreatitis in this study were classified as idiopathic. 
We believe that the incidence of DIP in this study may be somewhat underestimated. As 
will be discussed below, establishing the diagnosis of DIP often requires a re-evaluation and 
knowledge of the patient's post-episode history. 
On the other hand, at least two published studies showed a significantly higher incidence of 
DIP in retrospective analysis. A study by Mennecier et al., published 2007, found an 
incidence of drug-induced cases of 8.3 % among a total of 108 acute pancreatitis cases 
hospitalized in hepatogastroenterology and intensive care units of a French hospital over a 
9-year period. Our study, published in 2010, included 170 acute pancreatitis cases 
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hospitalized in a tertiary hospital during a period of two years. The proportion of DIP in this 
cohort was 5.3% (Vinklerová et al., 2010). Obviously, the incidence found in these studies is 
higher than in the general population. If DIP occurrence depends on the use of specific 
drugs, in tertiary hospitals as centers for the treatment of specific diseases (e.g. Crohn's 
disease or malignancies) it must be higher.  
The discrepancy in the published results demonstrates, in particular, the fact that the 
importance of drug-induced pancreatic injury will be different in the general population 
than among the cases reported in surgical or medical departments. It is also clearly 
improper to suppose that this disease can have similar incidence in all countries because of 
its dependence on the consumption of causative drugs and, secondarily, the dependence on 
the incidence of diseases treated with these medications. 
Studies with very low report of DIP are usually characterized by a high number of 
idiopathic acute pancreatitis cases. Clinicians sometimes forget that there is no such thing as 
an “idiopathic” disease. The word “idiopathic” means that we are not able to establish the 
actual cause of the disease – and a not insignificant number of idiopathic cases of acute 
pancreatitis might be caused by xenobiotics, including medication. The only way how to 
determine the real incidence of drug-induced acute pancreatitis is to perform prospective 
multicenter studies targeted at the etiology of non-alcoholic, non-biliary acute pancreatitis. 
3. Etiology 
The pathogenesis of acute pancreatitis is probably very uniform differing only by the initial 
injury mechanism. It consists of three steps: (i) premature activation of trypsin in acinar 
cells; (ii) intrapancreatic inflammation; and (iii) extrapancreatic inflammation (Banks & 
Freeman, 2006).  The mechanisms by which drugs initiate a cascade of damaging events 
remain shrouded in mystery. However, it should be borne in mind that the same is true for 
the vast majority of responses independent of drug dose. 
3.1 Mechanisms of injury 
Mechanism of medication's action against pancreas remains unknown. Two possible 
mechanisms of pancreatic injury caused by drugs are usually recognized, but in our 
opinion, at least three more possible mechanisms should be also mentioned: 
a. Direct toxic effect on pancreatic tissue; 
b. Idiosyncratic reaction; 
c. Influence of medication on the bile flow; 
d. Amplification of direct toxic effect of ethanol on pancreatic tissue; 
e. Secondary pancreatic damage. 
Simple direct toxic injury of pancreatic tissue, similar to the hepatic injury caused by some 
drugs or their metabolites (e.g. paracetamol), seems very unlikely in the majority of reported 
DIP cases. This (A-type) pattern of ADR is dose-dependent, irrespective of the patient's 
response, reproducible and usually occurs in much higher numbers than usual in DIP. 
Although acute pancreatitis sometimes develops under the condition of an overdose of 
some drugs, its incidence remains so rare that an underlying predisposition must play a role 
in these cases. Genetic differences in metabolism are usually supposed to be the most 
probable predisposing factor here. Only several drugs are reported as causing DIP by 
overdose: paracetamol (or acetaminophen), erythromycin and carbamazepine. We had an 
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opportunity to describe DIP in a patient overdosed on mycophenolate (Vinklerová et al., 
2001). Some kind of cumulative dose-dependent effect of toxic metabolites is also sometimes 
hypothesized in drugs showing a consistent long latency (more than 30 days) at the onset of 
the first episode of DIP. It is supposed mainly in valproate, but possibly also in didanosine, 
tamoxifen, chlorothiazide and estrogens. This would correspond to the C-type (continuous) 
of ADR, but other mechanisms can also explain the late onset of DIP in these agents. 
The definition of an idiosyncratic adverse drug reaction (B-type) best matches the actual 
characteristics of DIP. A strong correlation with some immune disorders (mainly Crohn's 
disease and HIV infections) implicates an immune-mediated reaction as a chief causative 
factor of the disease. Often, the latency between initiation of the drug and the onset of DIP is 
one week to one month, but later rechallenge led to a second episode in one to three days. 
The frequently mentioned lack of hypersensitivity symptoms (rash, fever, 
lymphadenopathy and eosinophilia) is of no major importance as it is rare in the majority of 
immune-mediated organ damage and cannot be considered pathognomic. An immune-
mediated process is undoubtedly the pathogenetic nature of many rare ADRs also 
connected with the drugs mentioned here, such as drug-induced pericarditis, lupus-like 
syndrome and, moreover, some types of drug-induced liver injury. It is possible that all 
these reactions have a common immune-mediated nature and the specific organ is injured in 
fact “accidentally” as a current locus minoris resistentiae. Unfortunately, there is as little 
evidence available for this hypothesis as there is for the others. This should lead us to study 
these rare ADRs more in terms of patient characteristics than those of individual drugs.  
The latter three mechanisms may not be as irrelevant as it might seem. Several drugs 
involved in acute pancreatitis have been implicated as causing cholestatic liver injury, e.g. 
azathioprine, cytarabine, estrogens and erythromycin. Codeine, morphine and possibly 
some other drugs can cause spasm of sphincter of Oddi. An interesting relationship between 
rofecoxib-induced cholestatic hepatitis and acute pancreatitis was observed (Sato et al, 2006). 
Human leukocyte antigen haplotype HLA-A33/B44/DR6 is involved in both these reactions 
reported simultaneously in several patients. Cholestatic hepatitis caused by this haplotype 
may induce secondary pancreatitis. Also, the occurrence of drug-induced pancreatitis in 
alcoholic patients has been described, but this issue has not been given much attention. 
Secondary (off-target) injury of pancreatic tissue is also possible in some drugs.  Known 
potential indirect effects of drugs on the pancreas comprise ischemia (azathioprine, 
diuretics), hypercalcemia (thiazide diuretics), thrombosis of pancreatic blood vessels 
(estrogens), and an increase in pancreatic juice viscosity (diuretics, pentamidine). 
3.2 Predispositions 
Several populations at higher risk have been identified during research in drug-induced 
pancreatitis. Predisposing demographic characteristics are female gender and younger age. 
The male-to-female ratio is inversed in comparison to other acute pancreatitis types, at least 
to 1:1.3. DIP is also more commonly reported in younger patients, not exceptionally in 
children. An increased risk in older patients with polypharmacy seems to be a bias: the risk 
is in the use of many drugs by a large segment of this population rather than old age itself. 
Three types of diseases were recognized as the most frequent predisposing health factors: 
inflammatory bowel diseases, HIV infection and cancer treated by combined chemotherapy. 
In patients with advanced HIV infection (CD4 counts < 200 cells/mm3), treated with 
antiretroviral drugs, an incidence of 14% was found, but incidence of up to 40% is also 
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mentioned (Trivedi et al., 2005). In an anticancer chemotherapy, the risk is also higher, but 
sometimes it is difficult to decide which of the multiple medications have caused the 
disease. The use of dexamethasone or cytarabine seems to be of the highest risk. 
The etiology of acute pancreatitis in patients with Crohn's disease was evaluated in a 
targeted study (Moolsintong et al., 2005). Among the 48 patients treated for Crohn's disease 
who had acute pancreatitis between 1976 and 2001, an ADR was the cause in 17% of cases 
with the vast majority being caused by purine analogs – azathioprine and 6-mercaptopurine. 
The most common etiologies of AP – biliary and alcoholic – were found only in 21% and 
15%, respectively. A higher risk of induction of AP in Crohn's disease was also proven by 
evidence in a study by Weersma et al. in which the risk was significantly higher in patients 
treated for Crohn's disease compared to the risk of those treated for autoimmune diseases or 
organ transplant. Also, a similar study performed by Bajaj et al. supports these findings. In 
ulcerative colitis, the risk is probably increased, but lower than in Crohn's disease. On the 
other hand, in a Danish population-based case-control study (1,590 incident cases of acute 
pancreatitis and 10 controls per case), a nearly four-fold increased risk of acute pancreatitis 
in patients with Crohn's disease and a 1.5-fold increased risk for ulcerative colitis were 
found, but the use of mesalazine or sulfasalazine was not associated with an increased risk 
(Munk et al., 2004). We suppose that this can be explained by the low proportion of DIP in 
the etiology of acute pancreatitis. In the population with a significantly increased risk, the 
number of medication-associated cases cannot influence the total risk. 
3.3 Experimental findings 
The obvious aim of experimental models is to mimic as closely as possible the conditions in 
an organism suffering from acute pancreatitis. Some of those models were based on the 
systemic administration of an exogenous substance. They are not considered to be best 
available for many reasons, but they can help in further research on DIP pathophysiology.  
Cerulein is a ten amino acid oligopeptide, similar to cholecystokinin, that stimulates gastric, 
biliary, and pancreatic secretion and also contraction of certain smooth muscles. It has been 
used by intravenous (as well as intraperitoneal or subcutaneous) route to cause acute 
pancreatitis in mice, rats, hamsters and dogs. Within one hour from application, cerulein 
causes pancreatic interstitial edema reaching a maximum in 12 hours. The supposed 
mechanism of action is the upregulation of NF-κB (nuclear factor κ-light-chain-enhancer of 
activated B cells) leading to activation of ICAM-1 protein and promotion neutrophil 
adhesion onto pancreatic acinar cells. An increase in digestive enzyme production and 
activation of NADPH oxidase could be supporting mechanisms. Pancreatitis caused by 
cerulein is mild, with negligible mortality (Su et al., 2006). 
L-arginine is one of the most common natural amino acids. If administered 
intraperitoneally, it causes acute pancreatitis in mice and rats. Significantly increased 
plasma amylase levels, pancreatic MPO activity, trypsin activation, and histological changes 
including accumulation of fluid, disruption of histoarchitecture, acinar cell vacuolization, 
extensive acinar cell necrosis, and neutrophilic infiltration have been described. It is 
believed that nitric oxide synthase (NOS), present in acinar cells and metabolizing L-
arginine, might play a role in the initiation of pancreatitis. Induction of NOS by L-arginine 
leads to an interaction of NO and superoxide radicals, which can generate peroxynitrite 
radicals causing cell injury (Dawra et al., 2007). Effects are dose dependent and a higher dose 
can lead to acute pancreatitis within a few hours. 
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It is worth noting that some drugs known to cause human DIP (e.g. azathioprine) are able to 
successfully suppress the development of acute pancreatitis in various experimental models. 
This supports the opinion that host factors (most probably the immune system) are more 
important for the development of DIP than the pharmacodynamic properties of causative 
agents. 
4. Causative drugs 
Several hundreds of chemical substances have been reported to cause acute pancreatitis in 
humans. The majority of these reports remain single with a limited level of evidence. Drugs 
causing pancreatic injury more frequently have been listed in several reviews, some of 
which tried to quantify the risk of individual agents. A comparison of the ability to cause 
drug-induced pancreatitis is very difficult as the probability of an adverse effect is 
conditioned by many population or individual risk factors. 
An interesting attempt to estimate the potential of individual drugs to cause DIP by 
pharmacoepidemiological methods was performed by Lancashire et al. in 2003. They 
examined the data held in the General Practitioner Research Database and compared the 
frequency of intake of different drugs by individuals with and without acute pancreatitis 
(3,673 cases of pancreatitis, 3 controls for each case). Odds ratios were calculated for recent 
(1–90 days before the episode), past (91–360 days before the episode) or continuing 
(prescription in both periods) use. A nine-fold increased risk in recent takers of mesalazine 
was found as well as a ten-fold increased risk in ever-takers of azathioprine in comparison 
to never-takers. Only a moderate risk was found for captopril and valproate. Strikingly 
increased odds ratios were found for recent takers of acid inhibitory drugs without having a 
peptic ulcer diagnosed. Although these drugs can certainly cause DIP, this is clearly a bias 
because their prescription is related to abdominal pain and other GIT symptoms preceding 
the diagnosis of acute pancreatitis. This result also shows the limitation of a study 
performed by using this method – no data on the etiology of acute pancreatitis were used. 
Estimating the risk of drugs to cause a rare ADR also requires a much greater population. 
There is no doubt that some diseases may predispose to the occurrence of acute pancreatitis 
in themselves. To distinguish the impact of this predisposition from the influence of 
medication, it will be necessary to carry out such studies in much larger cohorts. Therefore, 
a classification system based on the number of DIP reports appears to be the most 
appropriate way to assess the risk potential of a drug. 
4.1 Classification systems 
Because the risk potential of individual drugs is difficult to establish, it is generally 
estimated from the absolute numbers of published cases. In earlier critical reviews, the 
potential of a drug to induce AP was evaluated as definite, probable or possible (Mallory & 
Kern, 1980; McArthur, 1996). The current knowledge has recently been summarized and 
used to propose classification systems in papers published by Trivedi and Pitchumoni in 
2005 and Badalov et al. in 2007. 
Trivedi & Pitchumoni classified risk drugs on the basis of the search of the reported cases in 
the National Library of Medicine/Pubmed from 1966 to 2004. Drugs were indexed into 
Classes I-III: Class I drugs were medications implicated in greater than 20 reported cases of 
acute pancreatitis with at least one documented case following re-exposure; Class II 
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involved medications implicated in more than ten cases of acute pancreatitis; and Class III 
drugs were all other medications reported to be associated with pancreatitis.  
Also, Badalov et al. reviewed Medline reports of drug-induced AP from 1955 to 2006. The 
authors classified reported medications into four classes based on the published weight of 
evidence for each agent and the pattern of clinical presentation. Class I included 
medications in which at least one case was proven by a re-challenge with the drug. Class II 
included drugs with a consistent latency in 75% or more of the reported cases. Class III 
included drugs that had two or more case reports published, but neither a re-challenge nor a 
consistent latency period. Class IV drugs were similar to class III drugs, but only one case 
report had been found. 
An apparent weakness of all existing drug classifications is the lack of the knowledge on the 
relationship between the incidence of drug-induced AP and population exposure to the 
causative drugs. Quantifying this relationship is a challenge for pharmacoepidemiology. In 
addition, regular updating of existing classifications appears necessary because every year 
new cases of DIP occur, which may result in a reclassification of the drugs included. 
4.2 Drugs commonly associated with drug-induced pancreatitis 
Among several hundreds of drugs reported as causative for drug-induced pancreatitis, only 
a few have a sufficiently strong evidence base to be clearly associated with this rare adverse 
drug reaction. These agents are listed in Table 2. At least some of them also deserve more 
detailed mention, which can be found in following sections.. 
4.2.1 Azathioprine 
Azathioprine is a purine analog used in low doses as immunosuppressant. It is a pro-drug 
metabolized into the active 6-mercaptopurine, itself a purine synthesis inhibitor. Enzyme 
thiopurine S-methyltransferase (TPMT) deactivates 6-mercaptopurine. The most severe 
adverse effect of azathioprine is bone marrow suppression, especially in TPMT genetic 
polymorphism. Its adverse effects on the pancreas are well documented, so it is classified 
into class I according to the risk of induction of DIP by both classification systems. A 
significantly higher risk of azathioprine-induced acute pancreatitis was demonstrated in 
patients with Crohn's disease compared to all the others, including those with ulcerative 
colitis. Consistent latency of the DIP onset with an average of 25 days has been found. This 
adverse effect is neither dose related nor associated with myelotoxicity or the defect of 
TPMT. It is believed that the cause may be an immune-mediated response based on a 
genetic predisposition common to that predisposing to Crohn's disease. 
4.2.2 Mesalazine 
Mesalazine (mesalamine, 5-aminosalicylic acid) is an anti-inflammatory drug used to treat 
the inflammation of the digestive tract in ulcerative colitis and Crohn's disease. The 
mechanism of action remains unknown, but is limited to the intestine as the agent is not 
absorbed systemically in significant amounts. Therefore, systemic adverse reactions, e.g. 
interstitial nephritis and lupus-like syndrome, are uncommon and immune-mediated. 
Mesalazine belongs to drugs with the best documented association (Class I) with drug-
induced acute pancreatitis. Acute pancreatitis induced by mesalazine usually occurs during 
the first days or weeks of treatment; however, an occurrence following prolonged use has 
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also been sporadically reported. No dose dependence has been observed and the symptoms 
usually disappear within 10 days after drug withdrawal.  
 
Drug class Drug name Risk class 
Trivedi 
Risk class 
Badalov 
Usual onset 
latency 
Analgesics codeine* I Ia 1 day 
 paracetamol II II 1 day 
 sulindac I Ia > 30 days 
     
Anesthetics propofol III II 1 day 
     
Antidiabetics exenatide* - -  
 sitaglipin* - -  
     
Anti-infectives     
Antivirals didanosine I II > 30 days 
 lamivudine II Ib  
Antibacterials cotrimoxazole I Ia 1 – 30 days 
 erythromycin II II  1 day 
 tetracycline I Ia  
Antiparazitic agents pentamidine I Ib 1 – 30 days 
 stibogluconate* I Ia 1 – 30 days 
     
Anticonvulsants valproate I I and II > 30 days 
     
Antineoplastic agents asparaginase I II 1 – 30 days 
 cytarabine I Ib 1 – 30 days 
     
Cardiovascular drugs     
ACE inhibitors* enalapril II Ia > 30 days   
Diuretics furosemide I Ib  
Statins* pravastatin III Ia > 30 days 
     
Gastrointestinal drugs mesalazine I Ia 1 – 30 days 
 omeprazole III Ib > 30 days   
     
Steroid hormones estrogens* I Ib > 30 days 
 glucocorticoids* I Ib 1 – 30 days 
     
Immunosuppressants azathioprine  I Ib and II 1 – 30 days 
 sulfasalazine I Ia 1 – 30 days 
 
Table 2. Drugs commonly associated with drug-induced pancreatitis (* class effect probable) 
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4.2.3 Valproate 
Valproic acid is an anticonvulsant, acting as an inhibitor of GABA transaminase in the CNS 
and blocking the neuronal voltage-gated sodium channels and T-type calcium channels. 
Tens of DIP cases caused by its use have been reported, with 75% of them being observed in 
children. There is a long latency of the first episode onset (3–17 months) and a short one in 
rechallenge (6–12 weeks). Although usually mild, valproate-induced pancreatitis may have 
a severe course with associated complications such as necrosis or even death. 
4.2.4 Propofol 
Propofol is an intravenously administered general anesthetic with several proposed 
mechanisms of action, mainly the potentiation of GABAA receptor activity and blockade of 
neuronal sodium channels. The nature of an agent used as an anesthetic results in an 
immediate onset of drug-induced pancreatitis following a single use. At least 20 cases of 
propofol-associated acute pancreatitis have been reported in the literature with subsequent 
discussions on the possible role of drug formulation in the oil-in-water emulsion. Elevated 
serum lipids do not seem to be a reason for this ADR; the rarity of the ADR suggests an 
idiosyncratic nature (Jawaid et al., 2002). 
4.2.5 Enalapril and other ACE inhibitors 
ACE inhibitors belong to the most widely used and most effective cardiovascular drugs. In 
contrast to their wide use, the occurrence of acute pancreatitis caused by these agents is rare. 
The number of reported cases clearly depends on the time from introduction of the specific 
agent and its widespread use; thus, enalapril is the most commonly reported agent (Class II, 
Trivedi; Class Ia, Badalov). Some cases of a second episode of DIP caused by another drug 
with a similar mechanism of action suggest the class effect. The risk of acute pancreatitis in 
patients using cardiovascular drugs has been extensively studied in the European study on 
drug-induced acute pancreatitis. The use of ACE inhibitors has been associated with an 
increased risk of acute pancreatitis (adjusted odds ratio 1.5). The risk increased with higher 
daily doses and was highest in the first six months of therapy (Eland et al., 2006). 
4.2.6 Statins 
HMG-CoA reductase inhibitors are currently the most popular hypolipidemic agents. The 
number of DIP reports related to this drug class exceeded 50, most often concerning 
simvastatin and pravastatin. An odds ratio of 1.41 was found for the risk of acute 
pancreatitis in patients with a past history of exposure to statins (Singh & Loke, 2006). The 
risk appears to increase with the duration of treatment. The ability to cause pancreatitis is 
believed to be a class effect. 
4.3 Controversial issues: Acid-suppressing drugs 
The relationship between drugs suppressing the secretion of gastric acid and acute 
pancreatitis is a frequently discussed issue. Histamine H2 receptor antagonists cimetidine 
and ranitidine have been reported to cause drug-induced pancreatitis in several case reports 
without an evidence of rechallenge or a consistent latency. Some experimental findings also 
indicate the possible causative relationship, whilst others deny it. Also, in much more 
effective drugs with a similar effect, the proton pump inhibitors (PPIs, namely omeprazole), 
the risk of inducing pancreatitis has been described. In the above-mentioned study by 
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Lancashire et al., the odds ratios were extremely high for both H2-receptor inhibitors and 
PPIs. On the other hand, a previous, much larger and better designed study brought no 
evidence for this suspicion (Eland et al., 2000). We therefore believe that the relationship of 
these drugs with DIP is overestimated, perhaps with the exception of cimetidine. 
4.4 Controversial issues: Incretin-related antidiabetics  
Soon after the introduction of a new class of oral antidiabetic agents, stimulating receptors 
for glucagon-like peptide 1 (GLP-1), reports on acute pancreatitis caused by their use began 
to emerge. In a subgroup of direct GLP-1 receptor agonists, eight cases during clinical 
development and 36 cases in postmarketing surveillance were reported for exenatide (the 
first-of-class agent) and another four cases were reported for liraglutide (Anderson & 
Trujillo, 2010). This phenomenon was probably even more pronounced in a newer group of 
agents with similar effects, dipeptidyl peptidase-4 inhibitors. At least 88 cases of acute 
pancreatitis in patients using sitagliptin were reported to FDA until 2010 (Olansky, 2010).  
A considerable effort has been made to refute this connection, which is, of course, in the 
interest of the manufacturers. It has been found that the risk of acute pancreatitis is 
significantly higher in the diabetic compared to the non-diabetic population and that the use 
of drugs affecting the GLP-1 system does not further increase this risk (Garg et al., 2010). 
Here is yet another example of a negative result in a pharmacoepidemiological study. 
Again, the probable reason lies in an extremely small proportion of drug-induced cases in 
total numbers of acute pancreatitis, which of course cannot influence the overall risk in 
high-risk populations. Nevertheless, the number of DIP cases reported in these medications 
is exceptional and supports the hypothesis of an association between the use of these drugs 
and DIP. Only the future will reveal whether this new group of drugs will be more 
beneficial for the treatment of diabetes or for studying the pathogenesis of DIP.  
4.5 Toxins and illicit agents 
Acute pancreatitis caused by animal toxin poisoning has been sporadically described in the 
literature. Probably the best known are the effects of scorpion venom. Available clinical case 
reports or series are usually too outdated to rely on the information contained 
(Bartholomew, 1970), but experimental studies on the effects of scorpion toxin are very 
interesting. Concurrent stimulation of pancreatic secretion and contraction of the sphincter 
of Oddi have been demonstrated in the late 1970s. Recently, it has been proven that the 
venom from the Brazilian scorpion Tityus serrulatus and a purified fraction selectively cleave 
essential SNARE proteins within exocrine pancreatic tissue (Fletcher et al., 2010). Rare 
reports on pancreatitis caused by adder bite (venom containing neurotoxic phospholipase 
A2) or even blue-ringed octopus bite (venom containing tetrodotoxin) have been published.  
Aside from alcohol, another addictive substance often mentioned in association with acute 
pancreatitis is marijuana, abused by smoking. A smaller series of marijuana-induced 
pancreatitis cases was reported by Wargo et al. in 2007. The authors suggest a dose-related 
mechanism of pancreatic injury. Cannabinoid receptors CB1 and CB2 were found in the 
pancreas, so their stimulation might be a trigger of the proinflammatory cascade there. 
Interestingly, stimulation of cannabinoid receptors was found to be a protective mechanism 
during experimental pancreatitis. This is yet another example of ambivalent behavior of 
some xenobiotics towards the pancreatic tissue. The importance of smoking, as a route of 
THC administration, for the initiation of pancreatitis has not yet been reviewed. 
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5. Diagnostics, disease course and management 
Among the reasons why the real incidence of drug-induced acute pancreatitis is still not 
known, the difficulties in diagnosis are probably most important. Milder cases of pancreatic 
injury are often missed because serum amylase and lipase estimations are not part of the 
metabolic profile obtained during a routine health checkup and abdominal pain is often 
attributed to underlying diseases. Many cases of DIP are also erroneously classified as 
alcoholic or biliary in etiology often by default, whether they are causal or innocent 
bystanders. If acute pancreatitis is diagnosed, the treatment invariably includes exclusion of 
oral intake and, thus, also abolishment of causative oral medication and thereby the 
opportunity to diagnose DIP is missed (Trivedi & Pitchumoni, 2005). 
5.1 Diagnosis 
As is usual with the vast majority of idiosyncratic adverse drug reactions, no specific test for 
establishing the diagnosis of drug-induced pancreatitis is available. Therefore, the diagnosis 
is usually based on the following criteria:  
a. Acute pancreatitis occurs during the administration of a drug; 
b. All other common causes are excluded; 
c. Symptoms of acute pancreatitis disappear after drug withdrawal; 
d. Symptoms recur after a re-challenge of the suspected drug. 
These criteria bring some problems in all ADRs, not only in such a difficult one as DIP. The 
first criterion seems to be easy to achieve until we remember that monotherapy in our 
patients becomes more and more scarce. If DIP occurs in the later course of the 
pharmacotherapy, the decision which drug is most suspicious is not easy. Use of the 
classification systems mentioned above may be very useful for that purpose. 
Excluding all other causes of the disease is also not so straightforward in many cases of 
acute pancreatitis. However, modern diagnostic methods have led to a great progress in this 
area. The validity of diagnosis may depend on the equipment available and even more on 
the experience of the medical staff. From this point of view, previously published DIP case 
reports should also be considered since the possibilities of excluding other causes of acute 
pancreatitis are quite different now than they were in the 1970s. 
Disappearance of symptoms following drug withdrawal is also sometimes misleading. 
Discontinuation of oral therapy is a natural part of any management of acute pancreatitis. In 
patients treated by multiple pharmacotherapy, it is impossible to decide which medication 
withdrawal led to a resolution of the symptoms and laboratory findings. A similar problem 
occurs in drugs administered at once, e.g. general anesthetics or anticancer 
chemotherapeutics. In these cases, acute pancreatitis is usually diagnosed within several 
days from drug administration.  
Due to the character of the disease and ethical considerations, deliberate, repeated 
administration of suspect drug to induce a new episode of acute pancreatitis is not possible. 
Re-challenge is usually unintended, mainly if the cause of the first AP episode was not 
properly recognized. An exception is the use of essential drugs in cases where the benefits 
outweigh the risks. In such cases, the patient's written informed consent should be obtained. 
A simplified algorithm for diagnosing drug-induced pancreatitis is given in Figure 1. The 
suspected drug etiology should be considered after the exclusion of more common causes of 
illness. For the above reasons, it seems obvious that it is not always possible to establish a 
definitive diagnosis of drug-induced AP immediately. A "second-look" with the knowledge 
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of the subsequent patient's history may often be necessary. For that purpose, a proper 
documentation of each case is needed. A detailed medication history documentation is 
obvious as well as the determination of suspicious substances. We strongly recommend the 
use of scoring system of ADR probability and classification of suspicious drugs according to 
the DIP risk in the patient's files. 
 
 
Fig. 1. Algorithm for diagnosing drug-induced acute pancreatitis 
5.2 Probability scoring 
For the purposes of future re-evaluation of each DIP case, it is very useful to classify drugs 
involved in the event by the above classification systems. There is no evidence for preferring 
one of these systems, so it is possible to use both, mainly if there is a difference between 
them in classifying a specific suspicious agent. Assigning probability of causation to a 
suspected adverse drug reaction can be best done by using the WHO scoring system (see 
Table 3). Of course, the diagnosis of DIP comes into consideration only in the first three 
degrees of probability: certain, probable or possible. 
Definite diagnosis of acute pancreatitis 
Alcoholic or biliary etiology excluded 
Drugs with known risk used? 
Perform required tests 
NO 
YES 
Perform required tests  
NO 
Drug-induced etiology 
NO 
Other drugs used? 
YES 
Symptoms resolution following drug withdrawal 
YES 
YES 
Drug-induced etiology 
Drug-induced etiology probable 
Rechallenge test positive 
Rechallenge test negative 
Drug-induced etiology certain 
No rechallenge test 
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It is therefore appropriate that a record of the event in the patient's documentation should 
be written as follows: “Acute pancreatitis, drug induced; probability level: probable 
according to WHO scoring system; causative agent: azathioprine, class I according to 
Badalov”. Using these classification systems may improve the quality of information for 
further patient treatment and further processing of the event for scientific or 
pharmacovigilance purposes. 
 
Level of 
probability  
Characteristics 
Certain A clinical event, including a laboratory test abnormality, that occurs in a 
plausible time relation to drug administration, and which cannot be 
explained by concurrent disease or other drugs or chemicals 
 The response to withdrawal of the drug (dechallenge) should be clinically 
plausible 
The event must be definitive pharmacologically or phenomenologically 
using a satisfactory rechallenge procedure if necessary 
Probable A clinical event, including a laboratory test abnormality, with a 
reasonable time relation to administration of the drug, unlikely to be 
attributed to concurrent disease or other drugs or chemicals, and which 
follows a clinically reasonable response on withdrawal (dechallenge) 
 Rechallenge information is not required to fulfill this definition 
Possible A clinical event, including a laboratory test abnormality, with a 
reasonable time relation to administration of the drug, but which could 
also be explained by concurrent disease or other drugs or chemicals 
 Information on drug withdrawal may be lacking or unclear 
Unlikely A clinical event, including a laboratory test abnormality, with a temporal 
relation to administration of the drug, which makes a causal relation 
improbable, and in which other drugs, chemicals, or underlying disease 
provide plausible explanations 
Conditional / 
unclassified 
A clinical event, including a laboratory test abnormality, reported as an 
adverse reaction, about which more data are essential for a proper 
assessment or the additional data are being examined 
Unassessable / 
unclassifiable 
A report suggesting an adverse reaction that cannot be judged, because 
information is insufficient or contradictory and cannot be supplemented 
or verified 
Table 3. Causality assessment of suspected ADRs (Edwards & Aronson, 2000) 
5.3 Disease severity, management and secondary prevention 
It is believed that drug-induced pancreatitis usually has a mild course. Lankisch et al. in 1995 
showed that the disease course was usually favorable in patients with drug-induced AP, but 
more recent greater studies strongly suggest that the etiology of acute pancreatitis generally 
does not determine the severity (Gullo et al., 2002). Also, a number of deaths from DIP were 
reported, for example, in a Danish analysis of spontaneous reports, four (9%) out of 47 DIP 
episodes led to death (Andersen et al., 2001). Of course, severe cases tend to be more often 
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reported both in the literature and in spontaneous pharmacovigilance reports. Sometimes it 
may be rather difficult to decide to what extent DIP contributed to the death, especially in 
the presence of a severe, often end-stage underlying disease such as HIV infection or 
disseminated tuberculosis (Ksiądzyna, 2001). 
In the disease management, there are no specific issues concerning drug-induced 
pancreatitis, with an exception of an immediate withdrawal of the suspected drug. The 
treatment does not differ from other types of acute pancreatitis. A difficult question is how 
to reintroduce medication if the causative agent is not unambiguously identified. We 
recommend not introducing all withdrawn drugs at the same time to distinguish the cause 
of a possible flare-up. An agent with the lowest risk should be reintroduced first. The most 
suspected drugs should be substituted by their analogs with a different chemical structure. 
Secondary prevention consists of avoiding the drug which caused the episode of acute 
pancreatitis. Rechallenge of such an agent is justified only if its benefits outweigh the risks, 
as discussed above. 
The relationship between acute DIP and chronic pancreatitis is not known. Trivedi & 
Pitchumoni in their above cited paper hypothesized – on the basis of a known sequence in 
the pathogenesis of chronic pancreatitis – that prolonged use of a causative drug in a patient 
who experienced an episode of DIP may lead to chronic pancreatitis by causing repeated 
clinical or subclinical episodes of DIP but no evidence is available for this suggestion to date. 
6. Future research 
Given how inadequate the current state of knowledge on drug-induced pancreatic injury is, 
the area for further research in this field is remarkably wide. The majority of the knowledge 
on the topic has been obtained from case reports or their series. These will remain a major 
source of information, so it is necessary to improve their informative value substantially. 
The following recommendations for processing case reports on DIP were proposed by 
Balani & Grendell in 2008. Published case reports should: 
a. Provide the age and sex of the patient, along with the indication for treatment with a 
drug; provide the dose and frequency of medication;  
b. Document a definite case of pancreatitis based on current diagnostic guidelines;  
c. Provide information on the time course between initiation of drug and onset of 
pancreatitis;  
d. Exclude the most common causes of pancreatitis; document a positive response to 
withdrawal of medication;  
e. Provide the response to a rechallenge, if available. 
Higher level of knowledge may be obtained by performing multicenter studies targeted at 
the etiology of non-alcoholic, non-biliary pancreatitis. Several thousands of acute 
pancreatitis cases must be involved in these studies to reveal the actual occurrence of drug-
induced pancreatitis. Better cooperation between gastroenterologists and 
pharmacoepidemiologists is also needed to assess the actual risk of DIP for individual 
drugs. Any new pharmacoepidemiological study on this topic would be useful, but to 
improve the validity of its outcomes, substantially better input data are required. For this 
purpose, it would be optimal that each single case of acute pancreatitis included in such a 
study be documented according to the above principles. 
Integration of the research in different disciplines would also be very useful for studying the 
causes of DIP. An obvious field for this research is the issue of diseases with a high 
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incidence of this disorder. Identifying the genetic differences predisposing to pancreatic 
injury caused by medication in patients suffering from Crohn's disease or AIDS would be 
the most axiomatic target. Another issue is the experimental pharmacological research of 
mechanisms by which xenobiotics can damage the pancreatic tissue as well as the common 
mechanisms of immune-mediated tissue injury caused by drugs. Any substantial progress 
in this research can contribute to a progress in two scientific challenges: recognizing the 
nature of more frequent causes of acute pancreatitis and also recognizing the cause and 
pathogenesis of idiosyncratic adverse drug reaction. 
7. Conclusion 
Drug-induced injury is a rare cause of acute pancreatitis. Epidemiological studies show a 
very wide range of its incidence, but at least the absolute number of its cases is undoubtedly 
increasing. We are able to identify the drugs with the greatest risk and populations at risk, 
but the absolute risk for medication users is still very low. On the other hand, the 
pathogenesis of the disease remains completely unknown. A better understanding of drug-
mediated pancreatic injury can also help to understand the etiology of more common types 
of acute pancreatitis. Research in drug-induced acute pancreatitis is both a challenge and an 
opportunity to improve the collaboration of gastroenterology and clinical pharmacology. 
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